DiaCarta, Inc.
PrivateLast Round
Reverse Merger
Oct 14, 2022
Total Funding Raised
$55.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
DiaCarta, Inc. operates in Healthcare & Life Sciences and is based in Hayward, California. Its latest recorded funding round was a Grant round in October 2018.
DiaCarta, Inc. is a biotechnology company that develops and provides precision molecular diagnostic tests and services for oncology and infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DiaCarta, Inc. Comparables
Compare DiaCarta, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Predicine | 86% | |
| Lucence | 83% | |
| Datar Cancer Genetics | 79% |
For institutional investors. Book with your work email.
DiaCarta, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Reverse Merger | Oct 14, 2022 | ||||
| Grant | Oct 15, 2018 | ||||
| Grant | Jun 1, 2018 | ||||
| Series B | Feb 12, 2018 | ||||
| Grant | Oct 26, 2016 | ||||
Series A | Jan 9, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
DiaCarta, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Fortune Fountain Capital | Series B |
| BVCF | Series A |
| HH&L Acquisition Co. | Reverse Merger |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 35, representing 97% of headcount.
- Jan 20, 2026
Monthly visitors increased 113% MoM, reaching 3.4K.
For institutional investors. Book with your work email.
DiaCarta, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about DiaCarta, Inc.'s valuation, stock price, and market status.
Is DiaCarta, Inc. a public or private company?
DiaCarta, Inc. is a private company.
What is the current stock price of DiaCarta, Inc.?
DiaCarta, Inc. is a private company, so its shares have no public market price. Caplight tracks DiaCarta, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is DiaCarta, Inc. worth (valuation)?
Valuation information for DiaCarta, Inc. is not publicly available.
Can I buy DiaCarta, Inc. stock?
DiaCarta, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was DiaCarta, Inc.'s last funding round?
DiaCarta, Inc.'s most recent funding round was Reverse Merger on October 14, 2022.
Who are the main investors in DiaCarta, Inc.?
Key investors in DiaCarta, Inc. include Fortune Fountain Capital, BVCF.
Will DiaCarta, Inc. IPO soon?
No public IPO plans have been announced for DiaCarta, Inc..
How can I track DiaCarta, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in DiaCarta, Inc.'s shares on secondary markets.